1. Home
  2. NN vs CDNA Comparison

NN vs CDNA Comparison

Compare NN & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NN
  • CDNA
  • Stock Information
  • Founded
  • NN 2007
  • CDNA 1998
  • Country
  • NN United States
  • CDNA United States
  • Employees
  • NN N/A
  • CDNA N/A
  • Industry
  • NN Industrial Machinery/Components
  • CDNA Medical Specialities
  • Sector
  • NN Industrials
  • CDNA Health Care
  • Exchange
  • NN Nasdaq
  • CDNA Nasdaq
  • Market Cap
  • NN 1.8B
  • CDNA 1.0B
  • IPO Year
  • NN N/A
  • CDNA 2014
  • Fundamental
  • Price
  • NN $15.93
  • CDNA $19.24
  • Analyst Decision
  • NN
  • CDNA Buy
  • Analyst Count
  • NN 0
  • CDNA 6
  • Target Price
  • NN N/A
  • CDNA $30.33
  • AVG Volume (30 Days)
  • NN 1.4M
  • CDNA 939.7K
  • Earning Date
  • NN 08-06-2025
  • CDNA 07-30-2025
  • Dividend Yield
  • NN N/A
  • CDNA N/A
  • EPS Growth
  • NN N/A
  • CDNA N/A
  • EPS
  • NN N/A
  • CDNA 1.07
  • Revenue
  • NN $6,162,000.00
  • CDNA $346,421,000.00
  • Revenue This Year
  • NN $18.26
  • CDNA $13.31
  • Revenue Next Year
  • NN $4.59
  • CDNA $15.46
  • P/E Ratio
  • NN N/A
  • CDNA $17.91
  • Revenue Growth
  • NN 51.10
  • CDNA 25.92
  • 52 Week Low
  • NN $6.47
  • CDNA $14.09
  • 52 Week High
  • NN $18.54
  • CDNA $34.84
  • Technical
  • Relative Strength Index (RSI)
  • NN 76.42
  • CDNA 54.70
  • Support Level
  • NN $14.54
  • CDNA $18.57
  • Resistance Level
  • NN $15.58
  • CDNA $19.84
  • Average True Range (ATR)
  • NN 0.85
  • CDNA 0.77
  • MACD
  • NN 0.16
  • CDNA -0.06
  • Stochastic Oscillator
  • NN 95.37
  • CDNA 60.53

About NN NextNav Inc.

NextNav Inc provides GPS service. The company NextNav TerraPoiNT system keeps critical infrastructure resilient with reliable Position, Navigation, and Timing services in the absence of GPS.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: